AIVL0.351%
as of Jul 17
DXCM
GrowthDEXCOM INC
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
Close · 3M
+10.11%
Held by 3 AI ETFs
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals16
Win rate88% (14/16)
Avg buy return+7.12%
AIVL · Weight decrease · 2d
WisdomTree's AIVL, which employs an AI to score US value stocks using fundamental and valuation metrics, showed consecutive decreases in its DXCM holding on July 14th and 15th. This movement suggests the AI, tasked with distinguishing genuine value from value traps within its approximately 100-stock portfolio, may be reassessing DXCM's attractiveness. Despite 16.15% revenue growth and a 33.83% ROE, the company's P/E of 31.07 and P/B of 9.43, coupled with a 13.4% return over the past 90 days pushing its price to 87% of its 52-week high, could indicate the AI perceives reduced valuation appeal compared to other opportunities. Such adjustments are typical during the fund's periodic rebalance cycle, as opposed to daily trading, reflecting a more considered shift in conviction.
weight 0.351% → 0.336% (-0.015 pp)·stock down 3.5% in the 30 days before
Jul 15·entry $72.73·now $75.69
+4.07%
since Jul 15
AIVL · Accumulation · 5d
AIVL displayed a pattern of gradual accumulation in DXCM, with its weight fluctuating but steadily increasing from 0.3288% to 0.3514% across several days in July. This cadence aligns with WisdomTree's periodic rebalancing schedule, where the AI manager is not making daily adjustments but rather incremental shifts. The AI likely identified DXCM as a compelling candidate within its pre-filtered US value-factor pool, given the stock's 13.0% decline over the past year, placing it at $72.73, or 81% of its 52-week high. While the company's PER of 31.07 and PBR of 9.43 are not traditionally low, the AI's algorithm, designed to distinguish genuine value from value traps, likely prioritized DXCM's strong underlying fundamentals, such as its 16.15% revenue growth and 33.83% ROE, making it an attractive addition at this price level.
weight 0.329% → 0.343% (+0.014 pp)·stock down 1.5% in the 30 days before
Jul 14·entry $74.12·now $75.69Drifting
+2.12%
since Jul 14
AIVL · Accumulation · 6d
DXCM's financial profile, featuring a PER of 31.07 and PBR of 9.43 alongside a robust 33.83% ROE and 16.15% revenue growth, presents a nuanced case for AIVL's selection. WisdomTree's AI, operating within a US value-factor pool and designed to distinguish genuine value from value traps, likely interprets these profitability and growth metrics as foundational strength, validating the current valuation despite multiples that appear higher than typical for value. The fund's gradual accumulation starting in early July aligns with the stock's -1.0% 30-day return and -11.3% 1-year return, positioning the current price at 83% of its 52-week high. This indicates the AI identified an attractive entry point, where the market had priced in some downside, allowing AIVL to build its position based on the underlying fundamental quality.
weight 0.310% → 0.351% (+0.042 pp)·stock up 2.1% in the 30 days before
Jul 13·entry $76.35·now $75.69Fresh
-0.86%
since Jul 13
AIVL · Accumulation · 6d
Trading at $76.35, 85% of its 52-week high, DXCM has seen a -12.5% 1-year return despite recent positive 30-day and 90-day performance. This previous decline likely positioned the stock within AIVL's pre-filtered US value-factor pool, where the AI assesses whether current valuation metrics like a 31.07 P/E and 9.43 P/B are justified by underlying financials. The AI's gradual accumulation suggests it views DXCM as a genuine value opportunity, supported by its 16.15% revenue growth and 33.83% return on equity, distinguishing it from less fundamentally sound 'value traps' despite its relatively high multiples. Such a systematic increase in weight over time, rather than an abrupt purchase, is consistent with an AI continuously scoring names and adjusting positions within its periodic rebalancing cycle.
weight 0.301% → 0.345% (+0.044 pp)·stock down 4.1% in the 30 days before
Jul 10·entry $74.96·now $75.69Fresh
+0.97%
since Jul 10
AIVL · Accumulation · 5d
AIVL has exhibited a gradual accumulation of DXCM, with its weight in the portfolio steadily rising from 0.3007% to 0.3446% over approximately ten trading days in early July. This incremental increase, rather than a sudden shift, aligns with an AI manager making adjustments within a periodic rebalance cycle. Despite DXCM’s PER of 31.07 and PBR of 9.43, the WisdomTree AI likely interprets the company's 16.15% revenue growth and 33.83% return on equity as indicators of a high-quality business. This quality, combined with a 1-year price depreciation of 13.2% placing the stock at $74.96, suggests the AI identified a genuine value opportunity stemming from a temporary valuation compression, distinguishing it from a value trap. The gradual accumulation while the stock registers recent positive 30-day and 90-day returns implies the AI is building into a recovering position.
weight 0.314% → 0.337% (+0.023 pp)·stock down 4.7% in the 30 days before
Jul 9·entry $73.02·now $75.69Drifting
+3.66%
since Jul 9
AIVL · Accumulation · 6d
WisdomTree's AIVL ETF, which employs AI to score names within a US value-factor pool, initiated a gradual accumulation of DXCM due to its strong underlying fundamentals. The AI, tasked with distinguishing genuine value from value traps, likely identified the stock's 33.83% ROE and 16.15% revenue growth as compelling attributes. This move occurred while the stock was trading at $73.02, having seen a 1-year return of -14.1%, a price adjustment that likely brought it into the fund's value-tilted universe for consideration. The weight increase from 0.3066% to 0.3446% over two weeks aligns with the fund's periodic rebalance schedule for its approximately 100 US value stocks, reflecting the AI's evolving conviction in DXCM.
weight 0.307% → 0.345% (+0.038 pp)·stock up 1.6% in the 30 days before
Jul 8·entry $74.06·now $75.69Drifting
+2.20%
since Jul 8
AIVL · Accumulation · 5d
DXCM's 33.83% return on equity and 16.15% revenue growth align with AIVL's AI criteria for strong fundamentals, emphasizing efficient capital utilization within its pre-filtered US value-factor universe. Despite a 29.07 PER and 9.43 PBR, the AI’s mandate is to distinguish genuine value from value traps, suggesting these metrics were deemed acceptable given the underlying business quality, particularly after the stock experienced a 12.5% decline over the prior year. The gradual accumulation of DXCM in AIVL's portfolio, observed from June 30 to July 7, 2026, occurred as the stock, priced at $74.06, had recently shown a 2.8% 30-day return and sat at 83% of its 52-week high, indicating a strategic entry point following its prior weakness.
weight 0.317% → 0.338% (+0.021 pp)·stock up 1.4% in the 30 days before
Jul 7·entry $73.57·now $75.69Drifting
+2.88%
since Jul 7
AIVL · Accumulation · 5d
DXCM currently trades at $73.57, well within its 52-week range of $54.84 to $89.53, though it has experienced a 16.0% decline over the past year despite a recent 30-day return of 2.0%. This significant year-long price depreciation likely brought DXCM into AIVL’s pre-filtered US value-factor universe. The AI then evaluated the company's fundamentals, weighing its 16.15% revenue growth and 33.83% ROE against its PER of 29.07 and PBR of 9.43. These underlying strengths, seen in a stock trading lower than its 52-week high, suggest the AI identified DXCM as a genuine value, prompting the observed gradual accumulation from 0.3140% to 0.3319% within the portfolio.
weight 0.314% → 0.332% (+0.018 pp)·stock down 0.5% in the 30 days before
Jul 6·entry $72.38·now $75.69Drifting
+4.57%
since Jul 6
AIVL · Accumulation · 5d
AIVL, which employs AI to identify genuine value from value traps within its approximately 100 US value stocks, likely saw an opportunity in DEXCOM INC after evaluating its underlying fundamentals. Despite a PER of 29.07 and a PBR of 9.43, the AI’s scoring system, which includes metrics like return on capital and margins, likely prioritized DXCM's strong 33.83% ROE and 16.15% revenue growth. The gradual accumulation in weight, rather than an abrupt shift, aligns with the fund’s periodic rebalancing schedule, allowing the AI to incrementally increase its position in a stock that has seen a -10.9% 1-year return and is currently trading at 80% of its 52-week high. This move suggests the AI's assessment of DXCM indicates a strong company becoming more attractive within its value-tilted universe.
weight 0.311% → 0.329% (+0.017 pp)·stock down 3.0% in the 30 days before
Jul 2·entry $71.25·now $75.69Drifting
+6.23%
since Jul 2
AIVL · Weight increase · 2d
Within AIVL's pre-filtered US value-factor pool, DXCM's P/E of 28.58 and P/B of 9.43 were evaluated against its strong underlying financials. The AI focused on the Health Care company's 16.15% revenue growth and 33.83% return on equity, suggesting a business with solid operational performance. These fundamental characteristics, combined with the stock trading at $69.75—78% of its 52-week high and still down 16.0% over the past year—likely signaled genuine value rather than a value trap. Consequently, the ETF increased its allocation to DXCM, showing a consecutive weight rise from 0.3114% to 0.3165% across June 23rd and 24th, even after the stock’s recent 14.1% 30-day return. This behavior demonstrates the AI’s distinction of compelling opportunities within its specific investment universe.
weight 0.311% → 0.317% (+0.005 pp)·stock down 3.3% in the 30 days before
Jun 24·entry $69.75·now $75.69Drifting
+8.52%
since Jun 24
AIVL · Weight decrease · 6d
DXCM currently trades at $69.07, sitting at 77% of its 52-week high, after a 30-day return of +14.0% following a 1-year decline of -19.4%. This recent upward movement, contrasting with its prior long-term dip, appears to have prompted AIVL's AI to consecutively decrease its weighting from 0.3587% on June 8 to 0.3114% by June 22. WisdomTree's AIVL seeks genuine value within a pre-filtered universe, and the AI’s evaluation of DXCM's valuation metrics—such as a PER of 29.07 and PBR of 9.43—likely deemed the stock less compelling as a value play given its renewed price momentum. Even with 16.15% revenue growth and 33.83% ROE, these multiples could signal a diminished value proposition within the ETF’s specific criteria after its recent appreciation, driving the AI's move to reduce exposure.
weight 0.359% → 0.311% (-0.047 pp)·stock down 3.3% in the 30 days before
Jun 22·entry $69.07·now $75.69
+9.58%
since Jun 22
AIVL · Weight decrease · 5d
DXCM is priced at $72.47, positioning it at 81% of its 52-week high following a 30-day return of 19.0%. This upward price movement prompted AIVL's AI, which evaluates names within a US value-factor pool to distinguish genuine value, to incrementally decrease its exposure. Despite DXCM's 16.15% revenue growth and 33.83% ROE, its PER of 30.06 and PBR of 9.43, as the stock moved up, likely diminished its relative attractiveness by the fund's valuation metrics. AIVL's weighting in DXCM consequently declined from 0.3507% on June 10th to 0.3290% by June 18th, indicating a periodic recalibration of its value score.
weight 0.359% → 0.329% (-0.030 pp)·stock up 8.2% in the 30 days before
Jun 18·entry $72.47·now $75.69
+4.44%
since Jun 18
AIVL · Weight decrease · 4d
The sequence of declining weights for DXCM, from 0.3507% to 0.3305% over several days, illustrates AIVL's periodic rebalancing in response to changing stock metrics. This gradual reduction aligns with WisdomTree’s AI-managed strategy, which scores names based on fundamentals and valuation metrics to identify genuine value within its US value-factor pool. Despite DXCM's 33.83% ROE and 16.15% revenue growth, its current PER of 30.94 and PBR of 9.43, particularly after a 30-day return of +18.0%, likely moved its valuation beyond the optimal range for AIVL's value focus. The AI's function is to distinguish genuine value opportunities from those that become less attractive from a valuation perspective, prompting this specific rebalancing move to reduce exposure to the Health Care sector stock.
weight 0.359% → 0.331% (-0.028 pp)·stock up 18.7% in the 30 days before
Jun 16·entry $73.16·now $75.69
+3.46%
since Jun 16
AIVL · Weight decrease · 3d
DXCM presents a PER of 30.94 and a PBR of 9.43, suggesting a higher valuation, while simultaneously showing a 33.83% Return on Equity and 16.15% revenue growth, indicating strong underlying business performance. AIVL’s AI-driven strategy prioritizes US value stocks, using both fundamental and valuation metrics to discern genuine value from potential traps within its pre-filtered universe. The consecutive weight decrease observed from June 10-12 occurred after DXCM experienced a significant 30-day return of +23.6%, pushing its price to $74.22, which is 83% of its 52-week high. This recent price appreciation likely amplified DXCM’s valuation multiples, leading the AI to recalibrate its score and reduce exposure as the stock's value proposition diminished relative to the fund's specific value-factor criteria.
weight 0.359% → 0.343% (-0.015 pp)·stock up 28.7% in the 30 days before
Jun 12·entry $75.37·now $75.69
+0.42%
since Jun 12
AIVL · Weight decrease · 2d
DEXCOM INC's valuation metrics, including a PER of 30.94 and PBR of 9.43, sit at the higher end for a stock within WisdomTree's US value-factor universe, despite its 16.15% revenue growth and 33.83% return on equity. These elevated multiples present a challenge for the AIVL fund, whose AI component aims to identify genuine value stocks while avoiding value traps. The consecutive weight decrease in AIVL's holding of DXCM, observed on June 10 and 11, corresponds with the stock's recent 30-day return of +26.4%, pushing its price to $75.25. This upward price movement, relative to the 52-week range where the stock now sits at 84% of its high, likely prompted the AI to reassess DXCM's valuation metrics and fundamental attractiveness against its internal scoring for the value factor. The AI, tasked with discerning true value from less compelling opportunities within its value-tilted universe, appears to be responding to the altered risk-reward profile brought on by the stock's rapid appreciation.
weight 0.359% → 0.346% (-0.013 pp)·stock up 23.1% in the 30 days before
Jun 11·entry $75.25·now $75.69
+0.58%
since Jun 11
AIVL · Weight increase · 2d
AIVL’s AI, specifically designed to distinguish genuine value from value traps within its pre-filtered US value-factor pool, drove the consecutive weight increase in DXCM. Operating among its approximately 100 US value stocks, the algorithm likely focused on DXCM's strong underlying fundamentals, particularly its 33.83% Return on Equity and 16.15% revenue growth. The WisdomTree fund's periodic rebalancing schedule enabled this upward adjustment, allowing the AI to recognize a more favorable risk-reward profile. This increased allocation suggests the AI identified a re-evaluation of DXCM's intrinsic value, perhaps seeing the recent 30-day price return of 31.8% as a confirmation of its previously undervalued position.
weight 0.336% → 0.359% (+0.022 pp)·stock up 25.8% in the 30 days before
Jun 8·entry $76.62·now $75.69Fresh
-1.21%
since Jun 8
AIVL · Weight decrease · 2d
weight 0.348% → 0.336% (-0.012 pp)·stock up 22.0% in the 30 days before
Jun 4·entry $72.59·now $75.69
+4.27%
since Jun 4
AIVL · Weight increase · 2d
WisdomTree's AIVL ETF, which employs AI to differentiate genuine value from potential traps within its ~100-stock US value pool, likely increased its allocation to DXCM during a periodic rebalance. The AI's scoring mechanism, which evaluates fundamentals like Return on Capital and valuation metrics, identified a more compelling value proposition for DXCM at its current price. With a 33.83% Return on Equity, the company’s efficient use of capital probably contributed to its improved score, especially after experiencing a 1-year return of -15.9%. This substantial weight increase to 0.3485% on June 1st signals the AI's calculated assessment that DXCM now represents a stronger investment within its value-tilted universe.
weight 0.267% → 0.348% (+0.082 pp)·stock up 25.7% in the 30 days before
Jun 1·entry $74.87·now $75.69Fresh
+1.10%
since Jun 1
+30.91%
since May 14
+27.57%
since May 11
+24.27%
since May 7
+27.25%
since May 5
+23.37%
since May 1
+31.50%
since Apr 29
+27.60%
since Apr 28
AIEQ · Weight increase · 2d
Amplify ETFs' AIEQ, leveraging IBM Watson NLP for its daily ranking across thousands of US equities, initiated a position in DXCM, then increased it, aligning with its high-turnover, 140-180 stock portfolio. This fund’s broad market, fundamentals + sentiment hybrid style likely detected a positive shift in its analysis of news, filings, and social posts around DXCM following its recent price decline. Despite a -10.9% one-year return, the company’s 16.15% Revenue Growth and 33.83% Return on Equity likely provided a strong fundamental underpinning for the AI's re-evaluation. The move from 0.0000% to 0.2100% then 0.2200% over two trading days suggests the model identified an emerging buying opportunity as the stock trades at 80% of its 52-week high.
weight 0 → 0.220% (new)·stock down 3.0% in the 30 days before
Jul 3·entry $72.38·now $75.69Drifting
+4.57%
since Jul 3
AIEQ · New entry · 1d
weight 0 → 0.210% (new)·stock down 8.0% in the 30 days before
Jul 1·entry $68.86·now $75.69Drifting
+9.92%
since Jul 1
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of May 2
The AI ETFs, specifically AIVL, are showing a recent trend of decreasing their weight in Dexcom. This observed selling activity aligns with the framework's 'Fail' verdict, which primarily stems from concerns regarding a lack of sufficient margin of safety at the current price and incomplete financial health data.
- Circle of CompetenceThe unit economics of continuous glucose monitoring, with recurring sensor sales for a chronic condition, appear sufficiently stable and predictable for reasonable ten-year cash flow projections.
- Economic MoatDexcom benefits from a durable economic moat comprised of strong brand recognition, patient and provider switching costs, and regulatory and patent barriers to entry in the medical device market.
- ManagementThe provided financial data is insufficient to assess management's candor, capital allocation discipline, or their personal stake in the company.
- Financial HealthDespite a strong recent ROE, the absence of 10-year ROE data, operating margins, detailed debt figures, and owner earnings prevents a comprehensive assessment against the framework's financial health criteria.
- Margin of SafetyThe current valuation multiples for Dexcom (PER 28.38, PBR 9.43, EV/EBITDA 22.39) appear high, making it difficult to identify a defensible discount to intrinsic value for a sufficient margin of safety.
Dexcom operates within a predictable circle of competence and possesses a strong economic moat, suggesting a high-quality business. However, the framework's assessment is hindered by insufficient data to evaluate management and key aspects of financial health, leading to a 'Fail' on that stage. Moreover, the current valuation does not present a clear margin of safety, resulting in an overall 'Fail' verdict.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.